Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Indoximod |
Synonyms | |
Therapy Description |
Indoximod (D-1MT) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases metabolism of tryptophan to kynurenine, potentially resulting in increased T-cell proliferation and activation and enhanced anti-tumor immune response (PMID: 17234791, PMID: 32637034, PMID: 34117113). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Indoximod | D-1MT|1-MT|NLG-8189 | IDO1 Inhibitor 12 | Indoximod (D-1MT) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases metabolism of tryptophan to kynurenine, potentially resulting in increased T-cell proliferation and activation and enhanced anti-tumor immune response (PMID: 17234791, PMID: 32637034, PMID: 34117113). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02073123 | Phase Ib/II | Ipilimumab Indoximod | Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma | Completed | USA | 0 |
NCT04049669 | Phase II | Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | Recruiting | USA | 0 |
NCT02077881 | Phase Ib/II | Indoximod Gemcitabine + Nab-paclitaxel | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT01792050 | Phase II | Docetaxel Indoximod Paclitaxel | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | Completed | USA | POL | 0 |
NCT02502708 | Phase I | Indoximod Temozolomide | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors | Completed | USA | 0 |
NCT02052648 | Phase Ib/II | Temozolomide Indoximod | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | Completed | USA | 0 |